Significant Contracts - Additional Information (Detail)		1 Months Ended		3 Months Ended
	Oct. 26, 2015 USD ($)	Apr. 30, 2021 USD ($)	Oct. 31, 2019 License	Mar. 31, 2022 USD ($) Option	Mar. 31, 2021 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2021 USD ($)	Jul. 01, 2021	Apr. 30, 2020 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-current deferred revenue				$ 12,323,000			$ 12,323,000
Current deferred revenue							1,011,000
Research and development expense				118,245,000	$ 70,620,000
General and Administrative Expense				28,021,000	24,517,000
Collaboration Expense				30,646,000	19,945,000
A&R JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net profits and net losses		40.00%						40.00%
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Nonrefundable upfront payment received	$ 75,000,000.0
Non-current deferred revenue				12,300,000			12,300,000
Transaction price allocated to remaining performance obligations				12,300,000
Current deferred revenue				0			0
Maximum potential future payments				775,000,000.0
Collaboration Expense				30,600,000	19,900,000
Collaboration Expense Reimbursements Received				7,400,000	$ 10,600,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaboration Target Options [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable				420,000,000.0
Milestone payment receivable				410,000,000.0
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Joint Development Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received				$ 7,000,000.0
Agreement description				In connection with the JDA, the Company received a $7.0 million up-front payment from Vertex and subsequently received a one-time low seven-digit milestone payment upon the dosing of the second patient in a clinical trial with the initial product candidate.
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Exercise of Exclusive Option [Member] | Collaboration Target Options [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable				$ 10,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | 2019 Collaboration Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Nonrefundable upfront payment received				175,000,000.0
Maximum potential payments				$ 825,000,000.0
Percentage of exchange payment of research and development costs				50.00%
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | 2015 Collaboration Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable				$ 395,000,000.0
Percentage of exchange payment of research and development costs				50.00%
Number of options would not be exercised under agreement | Option				1
Number of remaining options under agreement | Option				4
Vertex Pharmaceuticals Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential future payments				$ 200,000,000.0
Vertex Pharmaceuticals Inc [Member] | Exclusive License [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated standalone selling price for single collaboration				900,000,000.0
Vertex Pharmaceuticals Inc [Member] | 2019 Collaboration Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable							$ 12,500,000		$ 25,000,000.0
Remaining Milestone Payment Receivable				775,000,000.0
Vertex Pharmaceuticals Inc [Member] | 2015 Collaboration Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Aggregate amount in option exercise payments received						$ 30,000,000.0
Number of exclusive license targets | License			3
Vertex Pharmaceuticals Inc [Member] | A&R JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received		$ 900,000,000.0		$ 900,000,000.0
Milestone payment receivable		$ 200,000,000.0
Percentage of net profits and net losses		60.00%						60.00%
Additional interest of percentage				10.00%